Real-life safety and effectiveness outcomes of teriflunomide in patients with relapsing–remitting multiple sclerosis: The TERICAM study
Introduction and objective: Teriflunomide is an oral immunomodulatory agent approved for the treatment of relapsing–remitting multiple sclerosis (RRMS). We examined teriflunomide outcomes in patients with RRMS under clinical practice conditions in Spain. Material and methods: Non-interventional, ret...
Main Authors: | M.L. Martínez-Ginés, J.M. García-Domínguez, J.P. Cuello, V. Meca-Lallana, C. Aguirre, L. Costa-Frossard, E. Monreal, S. Sainz de la Maza, P. Salgado-Cámara, A. Labiano-Fontcuberta, L. Fernández-Cabredo, Y. Aladro-Benito, L.B. Canelo, O.Sánchez-del Valle, M.R. Blasco, J. Sabin-Muñoz, A.B. Caminero-Rodríguez, J. Gracia-Gil, E. Fernandez-Diaz, A. Mendoza-Rodríguez, M. Gómez-Moreno, A. Orviz-García, I. Moreno-Torres, L.I. Casanova-Peño, A. Lozano-Ros |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-10-01
|
Series: | Neurology Perspectives |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S266704962300025X |
Similar Items
-
Effectiveness of comprehensive neurorehabilitation treatment on the cognitive function of patients with relapsing-remitting multiple sclerosis
by: Làzaro Aurelio Vàzquez Gòmez, et al.
Published: (2022-05-01) -
Caracterización clínica de pacientes con esclerosis múltiple
by: Roberto Luis Lotti Mesa, et al.
Published: (2023-03-01) -
Response to treatment with Interferon beta-1a in patients with relapsing-remitting multiple sclerosis
by: Làzaro Aurelio Vàzquez Gòmez, et al.
Published: (2022-10-01) -
Red cell distribution width as a predictor of disability in relapsing-remitting multiple sclerosis
by: R. Rocha, et al.
Published: (2022-04-01) -
Rituximab en el tratamiento de esclerosis múltiple. Experiencia de un hospital de tercer nivel en México
by: Jaime I. Castro-Macías, et al.
Published: (2023-07-01)